Influence of left ventricular ejection fraction on the clinical outcome of percutaneous coronary interventions in heart transplant patients - Report - MDSpire
Clinical Report: LVEF and PCI Outcomes in Heart Transplant Recipients
Overview
This retrospective study was designed to assess whether pre-procedural left ventricular ejection fraction (LVEF) is associated with survival and major adverse cardiac and cerebrovascular events (MACCE) among heart transplant recipients undergoing percutaneous coronary intervention (PCI). The supplied material describes the study population, methods, and endpoints but does not provide outcome results, so the association between LVEF and post-PCI outcomes cannot be stated.
Background
Cardiac allograft vasculopathy (CAV) is a major long-term complication after heart transplantation, affecting more than 50% of recipients by 10 years, and is associated with impaired prognosis and survival. Its progression can reduce coronary blood flow and impair myocardial function; treatment options include medication adjustment, PCI, bypass surgery, and retransplantation, although donor availability limits retransplantation. Outside transplantation, reduced LVEF has been associated with poorer outcomes, and even minor graft-function changes have been associated with increased mortality in heart transplant recipients. The source identifies limited evidence on interventional outcomes in this population and examines outcomes according to pre-PCI LVEF.
Data Highlights
Study feature
Details reported
Design and setting
Retrospective analysis at the University Clinic Herz- und Diabeteszentrum Nordrhein-Westfalen, Germany.
Population and period
Heart transplant recipients undergoing PCI from January 2011 through June 2023; transplant screening covered 1995–2022. Patients younger than 18 years were excluded.
LVEF groups
Preserved LVEF: >50%; reduced LVEF: ≤50%. LVEF was the most recent pre-intervention measurement, assessed by the biplane Simpson’s method.
Follow-up
Up to 3 years after the first PCI; each patient was included once.
Endpoints
Primary: all-cause mortality through a maximum of 3 years. Secondary: all-cause mortality and MACCE during the index hospitalization and at 3 months, 1 year, and 3 years. MACCE comprised all-cause mortality, myocardial infarction, stroke, and target vessel or target lesion revascularization.
Results available in supplied material
No cohort size, event rates, effect estimates, or comparative outcome results are provided.
Key Findings
The study sought to evaluate the prognostic relevance of pre-procedural LVEF for survival and MACCE after PCI in heart transplant recipients.
Patients were classified as having preserved LVEF (>50%) or reduced LVEF (≤50%); additional analyses were planned using HFrEF, HFmrEF, and HFpEF categories and per 1% LVEF increments.
The cohort included recipients undergoing PCI for stable CAV or acute coronary syndrome, with PCI defined as intervention on a lesion regardless of technical or procedural success.
The primary endpoint was all-cause mortality over up to 3 years; secondary assessments included mortality and MACCE at the index hospitalization, 3 months, 1 year, and 3 years.
The supplied article material does not report the study’s numerical results or conclusions about differences between LVEF groups.
The supplied guideline context describes CAV as a leading cause of late morbidity and mortality after transplantation and notes that revascularization options can be constrained by diffuse, rapidly progressive disease.
Clinical Implications
The provided methods establish how LVEF and post-PCI outcomes were assessed, but the absence of outcome data prevents conclusions about LVEF-based risk differences or clinical management. The supplied guideline context states that follow-up coronary angiography is recommended 6 months after PCI in transplant recipients because of high restenosis rates.
Conclusion
The source describes a retrospective evaluation of LVEF as a prognostic factor after PCI in heart transplant recipients, but the supplied material contains no results. Accordingly, it does not establish whether reduced LVEF is associated with mortality or MACCE in this cohort.
The proposed framework classified 30% of patients as high or extreme risk, compared with 12% classified as having severe or greater tricuspid regurgitation under established grading schemes.
Advanced heart failure does not always present as a single defining event. Referring physicians may instead notice a pattern of worsening symptoms, recurrent hospitalizations or increasing difficulty maintaining a patient’s clinical stability.
